Vaccibody rebrands as Nykode, and unveils big Regeneron partnership

Norwegian biotech Vaccibody has changed its name to Nykode Therapeutics, and celebrated its new identity with a sizeable deal with Regeneron to develop vaccines for cancer and infectious diseases. The Oslo-based company is getting $50 million upfront from Regeneron – split between cash and an equity investment – with another $875 million on the table …

Vaccibody rebrands as Nykode, and unveils big Regeneron partnership Read More »